August 17, 2023 News by Lindsey Shapiro, PhD Benefits of intranasal Nogo-A antibody observed in mouse model Delivering an antibody against the Nogo-A protein to a specific region of the nose called the olfactory mucosa improved motor function and preserved myelin in the spinal cord of a mouse model of multiple sclerosis (MS), according to a recent study. This intranasal mode of delivery enabled significant concentrations…
December 17, 2021 News by Marisa Wexler, MS Study: Anti-CD20 Therapies, Gilenya Lower Efficacy of COVID-19 Vaccines Certain treatments for multiple sclerosis (MS) ā specifically, anti-CD20 antibody therapies and Gilenya (fingolimod) ā are likely to reduce the effectiveness of vaccines for COVID-19, according to a new study. “Highlighting groups who have mounted an inadequate vaccine response has already been helpful in guiding who should receive…
June 1, 2021 News by Forest Ray PhD Nasal Foralumab Led to Promising Immune Effects in Phase 1 Trial Nasally-administered foralumab, a potential treatment for neurodegenerative disorders such as progressive forms of multiple sclerosis (MS), appears safe and well-tolerated, and shows immune-modulating and anti-inflammatory effects in healthy volunteers, an updated analysis from a Phase 1 trial has found. āNasal administration of Foralumab is a unique approach to treat…
May 26, 2021 News by Forest Ray PhD First SPMS Patient Dosed With Foralumab Nasal Spray Foralumab, an investigational anti-CD3 antibody that is administered via a nasal spray, has been given for the first time to a person with secondary progressive multiple sclerosis (SPMS). It was administered under an Individual Patient Expanded Access Program, which earnedĀ approval from the U.S. Food and Drug Administration in…
May 13, 2021 News by Patricia Inacio, PhD Therini Raises $17M to Bring Antibody to Myelin-damaging Protein Into Trials Therini BioĀ announced raising $17 million in a financing round to speed the development of an antibody that might treat people with inflammatory conditions, such as multiple sclerosis (MS), associated with damage to blood vessels. These funds will also support work aiming to move this antibody, targeting the protein…
April 21, 2020 News by InĆŖs Martins, PhD Potential Antibody Treatment for MS, by Immutep, Moving Toward Clinical Trials With the development of a cell line that produces significant amounts of Immutep‘s treatment candidate,Ā IMP761, the company is preparing to advance its antibody into clinical testing for autoimmune conditions, including multiple sclerosis (MS). Immutep also reports that is adapting its manufacturing operations to comply with…
October 31, 2018 News by Patricia Inacio, PhD National MS Society Invests in Clinical Development of Human Antibody for Progressive Forms of MS Fast Forward, a nonprofit subsidiary of theĀ National Multiple Sclerosis Society, will invest up to $330,000 to advance the clinical development of an antibody that was shown to lessen inflammation and nerve cell damage in a multiple sclerosisĀ (MS) mouse model. The funding will help develop the antibody (aĀ protein…
October 22, 2018 News by Ana Pena PhD Antibody Targeting Clotting Factor Seen to Lessen Inflammation, Nerve Cell Damage in MS Model An antibody that blocks a blood-clotting factor from leaking into the brain was seen to lessen neuroinflammation and nerve cell damage in mouse models of multiple sclerosis (MS) and Alzheimerās disease. Scientists developed an antibody that selectively inhibits the inflammation-triggering capacity of fibrin in…
May 14, 2018 News by Patricia Inacio, PhD Biomarker in Cerebrospinal Fluid Seen to Predict MS Progression in Study A potentialĀ biomarker ā the ratio of antibody proteins in cerebrospinal fluid at the time of diagnosis ā was seen to predict which Ā multiple sclerosis patients will progress into full-blow disability some five years after being diagnosed in a new study. If confirmed in larger clinical studies, this biomarker could to…
November 17, 2017 News by Alice MelĆ£o, MSc Nurses, Physicians’ Assistants Prescribe Antibody-based Therapies More Than Neurologists, Survey Shows U.S. nurses and physicians’ assistants prescribeĀ antibody-based disease-modifying therapies to their multiple sclerosis patients more than neurologists do, a survey indicates. The trend has been for the doctors to stick with interferon therapies, the study said. Antibody-based disease-modifying therapies are also known as monoclonal antibodies. They are designed to harness the…
June 28, 2017 News by Patricia Silva, PhD In Ongoing Phase 2 Trial, Ublituximab Seen to Effectively and Safely Deplete B-cells TG Therapeutics’ investigational treatment āĀ ublituximab (TG-1101)Ā ā led toĀ a near total depletion of B-cells in patients with relapsing forms of multiple sclerosis (MS) taking part inĀ an ongoing Phase 2 trial, the company recently announced. In addition, the company said that ublituximabĀ hadĀ anĀ infusion time as short as one hour,Ā without excessive side…
January 5, 2017 News by Joana Fernandes, PhD CHANGE-MS Phase 2 Study Fully Enrolled Early, Results Due in Fall GeNeuro recently announced that it has finished enrolling multiple sclerosis (MS) patients in the CHANGE-MS Phase 2b Ā studyĀ ā several months ahead of schedule.Ā The company nowĀ expects to reportĀ topline results in mid- to late autumn rather than at year’s end. āCompleting enrollment in CHANGE-MS several months sooner than previously anticipated…